Antiallergic marine biopolymers
AssigneeMarinomed Biotechnologie GmbH
InventorsAndreas GRASSAUER, Eva PRIESCHL-GRASSAUER
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions for administration to the respiratory tract, the gastrointestinal tract or the eyes. In particular, the invention relates to liquid formulations and dry powder compositions comprising carrageenan, and in particular iota and kappa carrageenan, and one or more therapeutic agents. These sprays, powders, and the gel that forms when they are administered to the respiratory tract, the gastrointestinal tract or the eyes, have now surprisingly been found to be a very effective way of prevention and treatment of type I allergies and intranasal administration of therapeutic agents.
Claims13
A method of prophylactic or therapeutic treatment of allergic rhinitis, allergic conjunctivitis or allergic asthma, comprising administering to mucosal surfaces of the respiratory tract or the eyes of a subject of pharmaceutical composition comprising iota-carrageenan in an anti-allergic effective amount, with the proviso that the iota-carrageenan is substantially free of lambda-carrageenan.
Dependencies are inferred from the claim text.